These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38086333)

  • 21. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
    Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
    Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets.
    Griger J; Widholz SA; Jesinghaus M; de Andrade Krätzig N; Lange S; Engleitner T; Montero JJ; Zhigalova E; Öllinger R; Suresh V; Winkler W; Lier S; Baranov O; Trozzo R; Ben Khaled N; Chakraborty S; Yu J; Konukiewitz B; Steiger K; Pfarr N; Rajput A; Sailer D; Keller G; Schirmacher P; Röcken C; Fagerstedt KW; Mayerle J; Schmidt-Supprian M; Schneider G; Weichert W; Calado DP; Sommermann T; Klöppel G; Rajewsky K; Saur D; Rad R
    Cancer Cell; 2023 Jul; 41(7):1327-1344.e10. PubMed ID: 37352862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.
    Dam G; Grønbæk H; Sundlöv A; Botling J; Sundin A; Petersen RH; Welin S; Evensen ET; Sorbye H; Tabaksblat E; Arveschoug AK; Mortensen J; Kjaer A; Knigge U; Tiensuu Janson E; Langer SW
    Acta Oncol; 2023 May; 62(5):431-437. PubMed ID: 37194281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
    Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
    Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.
    Uccella S; La Rosa S; Metovic J; Marchiori D; Scoazec JY; Volante M; Mete O; Papotti M
    Endocr Pathol; 2021 Mar; 32(1):192-210. PubMed ID: 33433884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.
    Park HK; Kwon GY
    J Korean Med Sci; 2023 Mar; 38(11):e85. PubMed ID: 36942393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
    Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
    Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
    Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
    Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?
    Volante M; Mete O; Pelosi G; Roden AC; Speel EJM; Uccella S
    Endocr Pathol; 2021 Mar; 32(1):154-168. PubMed ID: 33641055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
    Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
    Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
    Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
    Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of undifferentiated neuroendocrine tumors.
    Mitry E; Rougier P
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):47-51. PubMed ID: 11164718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors.
    Komatsu H; Kakehashi A; Nishiyama N; Izumi N; Mizuguchi S; Yamano S; Inoue H; Hanada S; Chung K; Wei M; Suehiro S; Wanibuchi H
    Cancer Biomark; 2013; 13(3):171-80. PubMed ID: 23912489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
    Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
    Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biology and evolution of poorly differentiated neuroendocrine tumors.
    Rickman DS; Beltran H; Demichelis F; Rubin MA
    Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
    Sun TY; Hendifar A; Padda SK
    Curr Oncol Rep; 2022 Jul; 24(7):819-824. PubMed ID: 35305210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.
    Fernandez-Cuesta L; Sexton-Oates A; Bayat L; Foll M; Lau SCM; Leal T
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390794. PubMed ID: 37229617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
    Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
    Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.